6YC Stock Overview
A medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Senzime AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.53 |
| 52 Week High | kr0.70 |
| 52 Week Low | kr0.23 |
| Beta | 0.50 |
| 1 Month Change | 3.11% |
| 3 Month Change | -11.67% |
| 1 Year Change | 26.19% |
| 3 Year Change | -74.40% |
| 5 Year Change | n/a |
| Change since IPO | -75.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6YC | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -8.1% | 3.0% | 1.6% |
| 1Y | 26.2% | -0.6% | 7.3% |
Return vs Industry: 6YC exceeded the German Medical Equipment industry which returned -3.1% over the past year.
Return vs Market: 6YC exceeded the German Market which returned 6.5% over the past year.
Price Volatility
| 6YC volatility | |
|---|---|
| 6YC Average Weekly Movement | 7.6% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 6YC's share price has been volatile over the past 3 months.
Volatility Over Time: 6YC's weekly volatility has decreased from 13% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 52 | Philip Siberg | www.senzime.com |
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance to measure the tissue’s opposition to carrying an alternating electrical current. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd.
Senzime AB (publ) Fundamentals Summary
| 6YC fundamental statistics | |
|---|---|
| Market cap | €67.45m |
| Earnings (TTM) | -€11.31m |
| Revenue (TTM) | €3.50m |
19.3x
P/S Ratio-6.0x
P/E RatioIs 6YC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6YC income statement (TTM) | |
|---|---|
| Revenue | kr40.59m |
| Cost of Revenue | kr29.73m |
| Gross Profit | kr10.86m |
| Other Expenses | kr142.13m |
| Earnings | -kr131.27m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 26, 2024
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 26.75% |
| Net Profit Margin | -323.45% |
| Debt/Equity Ratio | 0% |
How did 6YC perform over the long term?
See historical performance and comparison